Why Is MESOBLAST LTD ADR (MESO) Stock Moving Today?

MESO stock surged 9.14% to $17.02 on August 18, 2026, driven by the completion of patient treatment in its Phase 3 clinical trial for chronic low back pain. The trial, known as MSB-DR004, involves the allogeneic cell therapy rexlemestrocel-L and is a key milestone for the company. Investors are reacting positively to the progress, despite the fact that results are not expected until mid-2027.

What Happened

Mesoblast Limited announced that it has completed patient treatment in its Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain. This trial enrolled 350 patients and represents a pivotal step in the company's development pipeline. The completion of this phase is a major milestone for Mesoblast, which is a global leader in allogeneic cellular medicines for inflammatory diseases. The company has positioned this treatment to target a $10 billion market for regenerative back pain therapies. The news was reported by multiple sources, including InvestorsHub, The Fly, and Business Insider, all highlighting the significance of the trial's progress.

What The Data Shows

Despite the positive stock move, Mesoblast remains unprofitable, with a trailing twelve-month (TTM) earnings per share of -0.07 and a net margin of -144.3%. However, the company's revenue has grown significantly, rising 1,053.2% TTM. The stock has traded between $12.66 and $21.50 over the past 52 weeks. On August 18, it printed seven fresh 52-week lows, indicating a recent period of weakness before the rally. The stock's beta of 0.81 suggests it is less volatile than the broader market. The recent completion of the Phase 3 trial may signal a shift in investor sentiment.

What To Watch

The next key event for Mesoblast will be the release of Phase 3 trial results in mid-2027. Investors will be closely watching how the data is received by the market and whether it leads to regulatory submissions or partnerships. Coverage breadth is also a factor to monitor as the story continues to develop.